Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy

Abstract Background Lenvatinib is a novel tyrosine kinase inhibitor that exhibits an antitumor effect on hepatocellular carcinoma (HCC). An established strategy that involves surgery and usage of lenvatinib for advanced HCC remains elusive. Case presentation A 58-year-old male patient with advanced...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuki Ohya, Shintaro Hayashida, Akira Tsuji, Kunitaka Kuramoto, Hidekatsu Shibata, Hiroko Setoyama, Hironori Hayashi, Kazumi Kuriwaki, Masato Sasaki, Masayoshi Iizaka, Osamu Nakahara, Yukihiro Inomata
Format: Article
Language:English
Published: Japan Surgical Society 2020-12-01
Series:Surgical Case Reports
Subjects:
Hepatocellular carcinoma
Lenvatinib
Hepatectomy
Portal vein transection
Online Access:https://doi.org/10.1186/s40792-020-01078-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40792-020-01078-3

Similar Items